Skip to main content

Medicaite

Super-charging prescribers with AI. 30 days free, then only £2.95/month. Cancel anytime.

Join today Learn more

Super-prescriber

Become a cardiovascular super-prescriber. Let AI teach you state-of-the-art medication guideline recommendations.

Confidence

Learn to handle complex multi-morbidity with confidence by seeing the recommendations for difficult medication scenarios.

Fast and Efficient

Practise to reduce the time and stress of working out complicated treatment options.

How it Works

Input multiple disorders

Explore single disorders or complex multi-morbidity.

Acute coronary syndrome

Diabetes mellitus

Hypercholesterolaemia

Select AI-assisted smart features

Select around 15 features in under a minute.

Review recommended medications

Stratified by whether recommended in guidelines based on the smart features.

Recommended

SGLT2 inhibitor
Why?
aspirin 300 mg (oral) once only, then 75 mg (oral) every morning
Why?
atorvastatin 80 mg (oral) once daily
Why?
bisoprolol
Why?
metformin 500 mg (oral) once daily
Why?
ramipril 2.5 mg (oral) once daily
Why?
ticagrelor 180 mg (oral) once only, then 90 mg (oral) twice daily
Why?

Recommended as an option

alirocumab 75 mg (subcutaneous) every 2 weeks
Why?
evolocumab 140 mg (subcutaneous) every 2 weeks
Why?
ezetimibe 10 mg (oral) once daily
Why?
inclisiran 284 mg (subcutaneous) once only, then 284 mg (subcutaneous) every 6 months
Why?

Learn why each medication is recommended

Link directly to guidelines and BNF.

SGLT2 inhibitor
Based on the cardiovascular risk assessment for the person with type 2 diabetes: If they have chronic heart failure or established atherosclerotic cardiovascular disease, offer an SGLT2 inhibitor with proven cardiovascular benefit in addition to metformin. If they are at high risk of developing cardiovascular disease, consider an SGLT2 inhibitor with proven cardiovascular benefit in addition to metformin. [2022] See the rationale and impact section on first-line drug treatment for an explanation of 'proven cardiovascular benefit' [© NICE T2DM NG28 2022]
aspirin 300 mg (oral) once only, then 75 mg (oral) every morning
Offer aspirin to all people after an MI and continue it indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation (see the section on antiplatelet therapy for people with an ongoing separate indication for anticoagulation). [2007, amended 2013] [© NICE ACS NG185 2020]
Offer ticagrelor, as part of dual antiplatelet therapy with aspirin, to people with unstable angina or NSTEMI when PCI is not indicated, unless they have a high bleeding risk. [2020] [© NICE ACS NG185 2020]
For secondary prevention, offer people who have had MI treatment with the following drugs: angiotensin-converting enzyme (ACE) inhibitor dual antiplatelet therapy (aspirin plus a second antiplatelet) unless they have a separate indication for anticoagulation (see the section on antiplatelet therapy for people with an ongoing separate indication for anticoagulation) beta-blocker statin. [2007, amended 2020] [© NICE ACS NG185 2020]

Examples provided for demonstration purposes only. Not intended for clinical use. Guidance intended for a UK-only audience. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product.

Partners and Funders

NHS Clinical Entrepreneur Programme
NHS West Midlands Clinical Networks
Plug and Play
SPARK UK
West Midlands Health Tech Innovation Accelerator
University of Birmingham
Innovate UK

Our Team

Mark Thomas

Chief Executive Officer

Mark’s mission is to extend people’s time living in good health using state-of-the-art cardiovascular medicine and AI. He is one of the NHS’s few Preventive Cardiology Consultants and an Associate Professor of Cardiology with a PhD in cardiovascular pharmacology and over 50 publications.

James Dimmock

Chief Technical Officer

James has spent over 15 years building systems to scale to millions of users across the globe. He is passionate about building products that solve real user problems in a delightful way.